• Fernanda S Correia-Melo, Gustavo C Leal, Michelle S Carvalho, Ana Paula Jesus-Nunes, Carolina B N Ferreira, Flávia Vieira, Guilherme Magnavita, Lucas A S Vale, Rodrigo P Mello, Carolina Nakahira, Felipe C Argolo, Tanise Cardoso, Cezar D S Souza, Ana Teresa C Fontes, Marcelo B Ferreira, Lucas Araújo-de-Freitas, Marco A Tuena, Mariana V F Echegaray, Diogo E Cavalcanti, Ana C Lucchese, Igor D Bandeira, Manuela Telles, Cássio S Lima, Aline S Sampaio, Samantha S Silva, Roberta F Marback, José A Del-Porto, José Neander Abreu, Luciana M Sarin, Camilla S Paixão, Lucas P Carvalho, Paulo R L Machado, Gustavo Turecki, Lacerda Acioly L T ALT LiNC-Laboratório Interdisciplinar de Neurociências Clínicas. PRODAF-Programa de T, and Lucas C Quarantini.
• Postgraduate Program in Medicine and Health.
• Medicine (Baltimore). 2018 Sep 1; 97 (38): e12414.

IntroductionThe use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medication when compared to ketamine in the treatment of patients with treatment-resistant depression.Methods/DesignThis study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants will receive a single infusion of either esketamine (0.25 mg/kg) or ketamine (0.5 mg/kg) over 40 minutes. The primary outcome will be the difference in remission rates between the 2 treatment arms at 24 and 72 hours after drug infusion. Secondary outcomes will include other timepoints, measurements of cognition, dissociation, and blood biomarkers.DiscussionA head-to-head study is the best way to evaluate whether the esketamine is in fact comparable to the racemic ketamine in terms of both efficacy and safety, and, if positive, it would be an initial step to increase the access to that type of treatment worldwide.Ethics And DisseminationThe study was approved by the local Institutional Review Board (University Hospital Professor Edgard Santos-Federal University of Bahia-Number: 46657415.0.0000.0049). Subjects will only participate after voluntarily agreeing and signing the Informed Consent Form. The study findings will be published in peer-reviewed journals and presented at national and international conferences.Trial RegistrationThis trial has been registered in the Japan Primary Registries Network (JPRN): UMIN000032355, which is affiliated with the World Health Organization.

26 keywords...

hide…